Skip to content
777 Sourcing.

Capability

development of NLRP3 inflammasome antagonists

Suppliers
1
States & provinces
1
Countries
1

1 development of nlrp3 inflammasome antagonists supplier across 1 states and provinces in 1 country. Profiles show capabilities, materials, certifications, and facility locations so you can compare shops and build a shortlist.

Suppliers

AZOME THERAPEUTICS INC

MALVERN, PA

Azome Therapeutics is a drug discovery company developing selective antagonists of the NLRP3 inflammasome, an inflammatory pathway involved in diseases such as acute lung injury, Acute Respiratory Distress Syndrome, Bronchopulmonary Dysplasia, systemic sepsis, acute liver and kidney injury, and pneumonia. Its lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks an upstream priming signal in the aberrant activation of the NLRP3 inflammatory cascade. Initial indications target severe inflammatory pulmonary diseases with significant unmet need

drug discovery

Compiled from public sources

Related capabilities

Other processes offered by the shops that list development of NLRP3 inflammasome antagonists.

Browse all capabilities